Natural interferon-β treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study

Patti, Francesco; L'Episcopo, Maria Rita; Cataldi, Maria Lia; Reggio, A.

doi:10.1111/j.1600-0404.1999.tb00397.x

Cited by 9 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MS diagnosis was mainly based on the McDonald 2005 criteria [13] but there was some variation across trials. Most studies (84%) included over 100 patients, but seven included less [31][32][33][34][35][36][37]. Most (88%) had a cutoff for inclusion above an EDSS score of 5 or 5.5, with an average score across the trials ranging from 1.5 to 4.…”

Section: Creating and Defining The Networkmentioning

confidence: 99%

A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis

et al. 2020

View full text Add to dashboard Cite

Background: Since 2010, 27 mixed-treatment comparisons (MTCs) of disease-modifying therapies (DMTs) for multiple sclerosis have been published. However, there has been continued evolution in the field of MTCs. Additionally, limitations in methodological approach and reporting transparency, even in the most recent publications, makes interpretation and comparison of existing studies difficult. Objectives: The objectives of this study are twofold: (1) to estimate the efficacy and safety of DMTs at European Commission-approved doses compared with placebo in adults with relapsing-remitting multiple sclerosis (RRMS) using MTC, and (2) to identify and address methodological challenges when performing MTC in RRMS, thereby creating a baseline for comparisons with future treatments. Methods: Searches were completed in 14 databases, including MEDLINE, Embase, CENTRAL, CDSR and DARE, from inception to June 2018 to identify published or unpublished prospective, randomised controlled trials of all European Union-approved DMTs or DMTs expected to be approved in the near future in RRMS or rapidly-evolving severe RRMS. No language or date restrictions were applied. Studies were included in the MTC if they were judged to have sufficiently similar characteristics, based on the following: patient age; proportion of male participants; Expanded Disability Status Scale (EDSS) score; duration of disease; number of relapses prior to enrolment and proportion of previously treated patients. Background information from the included studies, as well as effect size and confidence intervals (where relevant) of defined outcomes were extracted. Reporting of the MTC was consistent with the Digital Features To view digital features for this article go to

show abstract

Section: Creating and Defining The Networkmentioning

confidence: 99%

A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…IFNB is the agent for which there is the best evidence of efficacy, and several large, placebo‐controlled RCTs have been published over the last few years [23–30]. These trials suggest a limited benefit in relapsing–remitting and secondary progressive MS, although all the trials have methodological limitations.…”

Section: Introductionmentioning

confidence: 99%

Hyperbaric Oxygen Therapy for Multiple Sclerosis

Bennett

Heard

2010

CNS Neuroscience & Therapeutics

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a chronic, inflammatory, and degenerative neurological illness with no cure. It has been suggested that Hyperbaric Oxygen Therapy (HBO(2)T) may slow or reverse the progress of the disease. This article summarizes the clinical evidence for the use of HBO(2)T in the treatment of MS. We conducted a literature review focused on the interaction of hyperbaric oxygenation and MS. In particular, we appraised the clinical data regarding treatment and performed a meta-analysis of the randomized evidence using the methodology of the Cochrane Collaboration. We found 12 randomized studies in the area, all of which were performed between 1983 and 1987. A meta-analysis of this evidence suggests there is no clinically significant benefit from the administration of HBO(2)T. The great majority of randomized trials investigated a course of 20 treatments at pressures between 1.75ATA and 2.5ATA daily for 60-120 min over 4 weeks against a placebo regimen. None have tested the efficacy of HBO(2)T against alternative current best practice. No plausible benefit of HBO(2)T on the clinical course of MS was identified in this review. It remains possible that HBO(2)T is effective in a subgroup of individuals not clearly identified in the trials to date, but any benefit is unlikely to be of great clinical significance. There is some case for further human trials in selected subgroups and for prolonged courses of HBO(2)T at modest pressures, but the case is not strong. At this time, the routine treatment of MS with HBO(2)T is not recommended.

show abstract